Published: January 2021

This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in substance use disorder (SUD) treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

Published: April 2016

This manual for clinicians describes the influence of culture on the delivery of substance use and mental health services. It discusses racial, ethnic, and cultural considerations, and presents the core elements of cultural competence.

Published: April 2016

This manual for administrators describes the influence of culture on the delivery of substance use and mental health services. It discusses racial, ethnic, and cultural considerations, and presents the core elements of cultural competence.

Published: November 2013

This guide helps clinicians of substance use disorder treatment facilities implement programs that address suicidal thoughts in patients with substance use disorders. It covers legal and ethical issues, referrals, as well as privacy and confidentiality.

Published: November 2013

This quick guide helps administrators of substance use disorder treatment facilities implement programs and services that address the needs of women living with substance use disorders. It addresses patterns of use and the drug screening and treatment needs of women.

Published: November 2013

This quick guide summarizes guidelines for clinicians treating chronic pain in adults living with a history of substance misuse. It covers patient assessment, chronic pain management, managing addiction risk in patients treated with opioids, and patient education.

Published: May 2010

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.